第十一批国家药品集采来了！本次集采有哪些新动向？一文解答→

Core Viewpoint - The release of the 11th batch of centralized drug procurement documents marks a significant shift in procurement strategies, focusing on stabilizing clinical drug supply and optimizing procurement measures [1][3]. Group 1: Changes in Procurement Rules - The new procurement rules allow medical institutions to report procurement volumes based on brand names as well as generic names, reflecting respect for clinical needs and choices of healthcare providers [3]. - The procurement process will no longer adopt the lowest bid approach, aiming for a more balanced evaluation of bids [1]. Group 2: Quality Control and Compliance - The new procurement guidelines emphasize higher quality control standards for bidding companies, prioritizing those with stable quality and clinical recognition [5]. - Companies found to engage in collusion or other violations will face strict penalties, including being banned from participating in centralized procurement for a minimum of 6 months and up to 5 years [9]. Group 3: Transparency and Fair Competition - The procurement process will adhere to principles of transparency and fairness, opposing excessive competition among bidders [11]. - All bidding companies are required to commit to not quoting below cost and must provide a rationale for any bids below the "anchor price," detailing cost components such as manufacturing costs and profit margins [11].